{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Grohskopf_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 6,
    "verified": 4,
    "rejected": 2,
    "verification_rate": 0.6666666666666666
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines).",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content of standard-dose flu vaccines (45 \u00b5g vs 15 \u00b5g per virus). It also groups RIV4 (Flublok) with 'higher dose vaccines' and distinguishes it from standard dose vaccines, which substantiates the first part of the claim. While the quote does not explicitly state that this higher antigen content 'has been linked to greater immunogenicity,' the surrounding text in the document (page 14) discusses that HD-IIV and RIV have shown relative benefit compared with SD-IIVs in certain studies, particularly in prevention of influenza-associated hospitalizations, and mentions immunogenicity. Therefore, the quote, in context, genuinely supports the claim as stated.",
      "presence_explanation": "The quote appears on page 9 of the document: 'Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines).' The numbers and technical content match the quote to verify.",
      "support_explanation": "The quote directly supports the claim that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content of standard-dose flu vaccines (45 \u00b5g vs 15 \u00b5g per virus). It also groups RIV4 (Flublok) with 'higher dose vaccines' and distinguishes it from standard dose vaccines, which substantiates the first part of the claim. While the quote does not explicitly state that this higher antigen content 'has been linked to greater immunogenicity,' the surrounding text in the document (page 14) discusses that HD-IIV and RIV have shown relative benefit compared with SD-IIVs in certain studies, particularly in prevention of influenza-associated hospitalizations, and mentions immunogenicity. Therefore, the quote, in context, genuinely supports the claim as stated.",
      "original_relevance": "This quote explicitly states that RIV4 (Flublok Quadrivalent) contains 45 \u00b5g of HA antigen per virus, which is 3 times the amount in standard dose inactivated vaccines (15 \u00b5g), directly supporting the claim about antigen content."
    },
    {
      "id": 2,
      "quote": "Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It explicitly states that RIV4 (Flublok) contains 45 \u00b5g of HA antigen per virus, which is 3 times the 15 \u00b5g in standard-dose inactivated vaccines. It also states that HD-IIV, RIV, and aIIV have shown 'relative benefit compared with SD-IIVs in certain studies,' which is a direct reference to greater immunogenicity or effectiveness. Thus, the quote both confirms the 3x antigen content and links this higher content to greater immunogenicity/benefit versus standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 14 of the document, with only minor differences in formatting and wording that do not affect the factual content. The relevant passage is: 'Two of these vaccines, HD-IIV and RIV, are higher dose vaccines, which contain an increased dose of HA antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines). The adjuvanted vaccine contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted SD-IIVs, but contains the adjuvant MF59. HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3.' This matches the quote to verify in all essential facts and numbers.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that RIV4 (Flublok) contains 45 \u00b5g of HA antigen per virus, which is 3 times the 15 \u00b5g in standard-dose inactivated vaccines. It also states that HD-IIV, RIV, and aIIV have shown 'relative benefit compared with SD-IIVs in certain studies,' which is a direct reference to greater immunogenicity or effectiveness. Thus, the quote both confirms the 3x antigen content and links this higher content to greater immunogenicity/benefit versus standard-dose vaccines.",
      "original_relevance": "This quote confirms both the 3x HA antigen content of RIV4 (Flublok) compared to standard dose vaccines and that higher antigen content has been linked to greater immunogenicity (relative benefit) in studies."
    },
    {
      "id": 5,
      "quote": "One recombinant influenza vaccine, Flublok Quadrivalent (RIV4), is expected to be available during the 2022\u201323 influenza season. RIV4 is approved for persons aged \u226518 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell-derived influenza viruses and is manufactured without the use of influenza viruses or eggs (127). Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).",
      "supports_claim": true,
      "explanation": "The quote directly supports the first part of the claim by stating that Flublok Quadrivalent (RIV4) contains 45 \u00b5g of HA per virus strain per 0.5 mL dose, which is three times the 15 \u00b5g per strain found in standard-dose flu vaccines (as confirmed elsewhere in the document, e.g., page 19: 'Standard dose, nonadjuvanted IIV4 s contain 15 \u00b5g of HA per vaccine virus in a 0.5-mL dose'). The quote does not itself address immunogenicity, but the document elsewhere (page 14) states: 'Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose in activated vaccines)... HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies...' Thus, the quote, in the context of the document, supports the claim that Flublok contains 3x the HA antigen of standard-dose vaccines and that this has been linked to greater immunogenicity.",
      "presence_explanation": "The quote appears on page 21 of the document under the section 'Quad rival ent Recombinant Influenza Vaccine (RIV4)'. The text states: 'One recombinant influenza vaccine, Flublok Quad rival ent (RIV4), is expected to be available during the 2022\u201323 influenza season. RIV4 is approved for persons aged \u226518 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell derived influenza viruses and is manufactured without the use of influenza viruses or eggs (127). Dosage and Administration: RIV4 is administered by IM injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g of HA derived from each vaccine virus (180 \u00b5g total).' This matches the quote to be verified, with only minor formatting differences.",
      "support_explanation": "The quote directly supports the first part of the claim by stating that Flublok Quadrivalent (RIV4) contains 45 \u00b5g of HA per virus strain per 0.5 mL dose, which is three times the 15 \u00b5g per strain found in standard-dose flu vaccines (as confirmed elsewhere in the document, e.g., page 19: 'Standard dose, nonadjuvanted IIV4 s contain 15 \u00b5g of HA per vaccine virus in a 0.5-mL dose'). The quote does not itself address immunogenicity, but the document elsewhere (page 14) states: 'Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose in activated vaccines)... HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies...' Thus, the quote, in the context of the document, supports the claim that Flublok contains 3x the HA antigen of standard-dose vaccines and that this has been linked to greater immunogenicity.",
      "original_relevance": "This quote confirms the HA content per dose in Flublok Quadrivalent (RIV4) is 45 \u00b5g per virus, which is 3 times the standard dose, directly supporting the first part of the claim."
    },
    {
      "id": "comp_1",
      "quote": "TABLE 1. Influenza vaccines - United States, 2022-23 influenza season... Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM... IIV4 (standard dose, egg based vaccines\u2020)... 15 \u00b5g/0.5 mL IM\u00b6",
      "supports_claim": true,
      "explanation": "The quote directly supports the first part of the claim by showing that Flublok (RIV4) contains 45 \u00b5g of HA per 0.5 mL dose, while standard-dose IIV4 contains 15 \u00b5g per 0.5 mL dose\u2014demonstrating that Flublok contains 3 times the HA antigen content of standard-dose flu vaccines. The table does not, by itself, state that this higher HA content is 'linked to greater immunogenicity vs standard-dose flu vaccines', but elsewhere in the document (page 14) it is stated that 'HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines)... have shown relative benefit compared with SD-IIVs in certain studies.' Thus, the document as a whole provides explicit support for both parts of the claim.",
      "presence_explanation": "The quote is found in the document, specifically in the section containing TABLE 1 on page 5. The table lists 'Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM' and for standard dose IIV4 (egg based vaccines), '15 \u00b5g/0.5 mL IM'. The numbers, vaccine names, and dose volumes match the quote, and the table is explicitly labeled as 'Influenza vaccines - United States, 2022-23 influenza season'.",
      "support_explanation": "The quote directly supports the first part of the claim by showing that Flublok (RIV4) contains 45 \u00b5g of HA per 0.5 mL dose, while standard-dose IIV4 contains 15 \u00b5g per 0.5 mL dose\u2014demonstrating that Flublok contains 3 times the HA antigen content of standard-dose flu vaccines. The table does not, by itself, state that this higher HA content is 'linked to greater immunogenicity vs standard-dose flu vaccines', but elsewhere in the document (page 14) it is stated that 'HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard dose vaccines (60 \u00b5g for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for standard dose inactivated vaccines)... have shown relative benefit compared with SD-IIVs in certain studies.' Thus, the document as a whole provides explicit support for both parts of the claim.",
      "original_relevance": "This table explicitly lists the HA content per dose for Flublok Quadrivalent (RIV4) as 45 \u00b5g/0.5 mL and for standard dose IIV4 as 15 \u00b5g/0.5 mL, directly supporting the claim that Flublok contains 3 times the HA antigen of standard-dose flu vaccines."
    }
  ],
  "rejected_evidence": [
    {
      "id": 3,
      "quote": "HD-IIV, RIV, and aIIV have shown relative benefit compared with SD-IIVs in certain studies, with the most evidence available for HD-IIV3. Randomized efficacy studies comparing these vaccines with nonadjuvanted SD-IIVs against laboratory-confirmed influenza outcomes are few in number (66\u201368) and cover few influenza seasons. Observational studies, predominantly retrospective cohort studies using diagnostic code\u2013defined (rather than laboratory-confirmed) outcomes, are more numerous and include more influenza seasons (69\u201379). Certain observational studies have reported relative benefit for HD-IIV, RIV, and aIIV in comparison with nonadjuvanted SD-IIVs, particularly in prevention of influenza-associated hospitalizations.",
      "reason": "does not support claim",
      "original_explanation": "This quote provides evidence that RIV (Flublok) has shown greater immunogenicity (relative benefit) compared to standard-dose vaccines in some studies, supporting the second part of the claim."
    },
    {
      "id": 4,
      "quote": "A retrospective analysis of relative effectiveness of RIV4 versus SD-IIV4 against influenza-coded hospitalizations among Medicare beneficiaries during the 2019\u201320 season noted a relative effectiveness of 17% (95% CI: 9\u201324; certainty level: 3, low) (72).",
      "reason": "does not support claim",
      "original_explanation": "This quote provides specific data showing that RIV4 (Flublok) was more effective than standard-dose IIV4 in preventing influenza-coded hospitalizations, supporting the link between higher HA content and greater immunogenicity."
    }
  ],
  "model_used": "gpt-4.1"
}